Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Organisation › Details

HalioDx S.A.S.

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immunooncology and combination therapies. Immunoscore® proprietary technology, pioneered by Dr Jérôme GALON at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a diagnostic solution for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications. HalioDx also develops assays such as Halioseek® and Immunosign® to help stratifying patients for immunotherapies. HalioDx has an experienced team of more than 130 employees, a CLIA laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. Based in Marseille, France, the company co-founded the European immunology cluster Marseille Immunopôle (MI). *


Period Start 2015-03-23 splitoff (MBO)
  Predecessor Qiagen Marseille S.A.
Products Industry molecular diagnostics
  Industry 2 Immunoscore® cancer prognosis tool
Persons Person Fert, Vincent (HalioDx 201503– CEO + CO-founder before Ipsogen 200708– President + CEO)
  Person 2 Galon, Jérôme (INSERM 201507 + Co-Founder of HalioDx)
Region Region Marseille
  Country France
  Street 163 avenue de Luminy
  City 13288 Marseille Cedex 09
  Tel +33-4-9129-3090
    Address record changed: 2018-07-24
Basic data Employees D: 101 to 500 (2017-09-08)
    * Document for �About Section�: HalioDx S.A.S.. (1/17/18). "Press Release: HalioDx Closed a Series B round of €18.5 Million (US$22.3 Million)". Marseille.
Record changed: 2018-09-12


Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for HalioDx S.A.S.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px

» top